Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10301828" target="_blank" >RIV/00216208:11110/15:10301828 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/15:00086570 RIV/00216208:11150/15:10301828 RIV/00216208:11120/15:43909772 RIV/61989592:15110/15:33156954 a 4 dalších

Výsledek na webu

<a href="http://dx.doi.org/10.1159/000381327" target="_blank" >http://dx.doi.org/10.1159/000381327</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1159/000381327" target="_blank" >10.1159/000381327</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?

Popis výsledku v původním jazyce

Background: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong CD20 expression. The role of rituximab in treating NLPHL still needs clarification. Methods: We retrospectively reviewed the outcome of 23 patients with NLPHL treated with rituximab alone or in combination with chemotherapy and/or radiotherapy as part of their first-or second-line treatment. Results: The median follow-up of the whole group was 67 months, and all patients remainedalive. Twenty-two patients achieved complete remission after rituximab-based therapy, and one of them relapsed 32 months after treatment. One patient treated with rituximab alone achieved partial remission and progressed 22 months after treatment. Conclusion: The prognosis of NLPHL is excellent. Rituximab combined with chemotherapy and/or radiotherapy appears to prevent disease progression/relapse. (C) 2015 S. Karger AG, Basel

Název v anglickém jazyce

Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?

Popis výsledku anglicky

Background: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong CD20 expression. The role of rituximab in treating NLPHL still needs clarification. Methods: We retrospectively reviewed the outcome of 23 patients with NLPHL treated with rituximab alone or in combination with chemotherapy and/or radiotherapy as part of their first-or second-line treatment. Results: The median follow-up of the whole group was 67 months, and all patients remainedalive. Twenty-two patients achieved complete remission after rituximab-based therapy, and one of them relapsed 32 months after treatment. One patient treated with rituximab alone achieved partial remission and progressed 22 months after treatment. Conclusion: The prognosis of NLPHL is excellent. Rituximab combined with chemotherapy and/or radiotherapy appears to prevent disease progression/relapse. (C) 2015 S. Karger AG, Basel

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Acta Haematologica

ISSN

0001-5792

e-ISSN

—

Svazek periodika

134

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

6

Strana od-do

187-192

Kód UT WoS článku

000361636000012

EID výsledku v databázi Scopus

2-s2.0-84930252027